We found that glypican-3 (GPC3), which is an oncofetal antigen that is overexpressed in human hepatocellular carcinoma (HCC), was shown to be a useful target antigen for immunotherapy in several studies (6–10). Here, GPC3 is linked to hepatocellular carcinoma.